Skip to main content
Toggle navigation
FR
EN
Drupal
Main navigation EN
About Crossject
Who we are
Governance
R&D
Our technology
ZENEO®: needle-free technology
Products under development
Our supply chain
Therapeutic areas
Migraines and cluster headaches
Anaphylactic shock
Acute adrenal crisis
Epileptic seizure
Opioid overdose
Rheumatoid arthritis
Temporary paralysis in Parkinson's disease
Severe asthma crisis
Main navigation 2 EN
Finances
Profile
Analyst coverage
Financial releases
News
Our news
Press releases
Careers
Working at Crossject
Available position and applications
Contact
Search
Search
Enter the terms you wish to search for.
Home
Finances
Financial releases
Financial releases
Release date
And
Year
All
2021
2020
2019
2018
2017
2016
2015
2014
2013
Apply
2021/10/05
First-half 2021 results and business update
Read the release
2021/06/16
US & Canada licensing agreement with Eton Pharmaceuticals for Crossject’s ZENEO® Hydrocortisone
Read the release
2021/04/08
2020 Annual results and business update
Read the release
2021/03/09
Crossject benefits from The French National Recovery Plan, with a €1.5 million grant
Read the release
2020/12/15
Crossject successfully raises €12 million in funding
Read the release
2020/09/21
First-half 2020 results and business update
Read the release
2020/07/17
Annual report 2019
Read the release
2020/07/07
End of the conversion of convertible bonds issued in 2019
Read the release
2020/07/06
Result of votes at Combined General Meeting of 25 june 2020
Read the release
2020/07/06
General meeting of 25 june 2020 - Q&R
Read the release
Pagination
Current page
1
Page
2
Page
3
Page
4
Page
5
Page
6
Next page
Next ›
Last page
Last »
